Hutchmed China Ltd ADR (HCM)

$14.48 +0.81 (5.93%)
Market Cap 2.38B
Revenue (ttm) 548.51M
Net Income (ttm) 456.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 59.43
Profit Margin 83.30%
Debt to Equity Ratio 0.07
Volume 113,600
Avg Vol 69,408
Day's Range N/A - N/A
Shares Out 174.47M
Stochastic %K 70%
Beta 0.24
Analysts Sell
Price Target $18.90

Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung c...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 852 2121 8200
Address:
Cheung Kong Center, 48th floor 2 Queen's Road Central, Hong Kong, Hong Kong
Avocado_smash
Avocado_smash Sep. 21 at 9:41 PM
$HCM
0 · Reply
OnlyFibs
OnlyFibs Sep. 9 at 12:23 AM
RECAP 9/8 +Pos Comments: $HCM + HSBC $BCRX + TD Cowen $VIK + UBS RECAP 9/8 -Neg Comments: $CRM - Accountability Research
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 8 at 8:00 PM
RECAP 9/8 +Pos Comments: $HCM + HSBC $BCRX + TD Cowen $VIK + UBS RECAP 9/8 -Neg Comments: $CRM - Accountability Research Live Breaking trading news www.openoutcrier.com
0 · Reply
DekmarTrades
DekmarTrades Sep. 3 at 1:29 PM
ENTIRE LIST OF CREDIBLE TOP GAINERS WITH NEWS: $MIMI $HCM $DLTH $GCO $SPWR
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 3 at 12:51 PM
$HCM (+12.5% pre) HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy https://ooc.bz/l/113161
0 · Reply
npcpaperboy
npcpaperboy Sep. 3 at 11:16 AM
$HCM news no vol
0 · Reply
STACKD0E
STACKD0E Sep. 3 at 10:18 AM
$HCM $FFAI 👁
0 · Reply
Polip
Polip Sep. 3 at 10:11 AM
$HCM Again this is very mispriced. should be trading at 40 $XBI
0 · Reply
notreload_ai
notreload_ai Sep. 3 at 9:51 AM
$HCM licenses HMPL-A830, a KRAS-EGFR ATTC, to $GSK for $110M upfront. Trials start H2 2026 in colorectal, pancreatic and lung cancers. https://notreload.xyz/xy/hutchmed-licenses-kras-egfr-cancer-drug-to-gsk/
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 31 at 12:18 PM
$HCM (+3.0% pre) HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China https://ooc.bz/l/112764
0 · Reply
Latest News on HCM
Hutchmed price target raised to $18 from $16 at BofA

2026-09-21T10:40:14.000Z - 13 hours ago

Hutchmed price target raised to $18 from $16 at BofA

HUTCHMED (China) Ltd (HCM) Stock Down 3.2% -- Now Undervalued? GF Score: 81/100

2026-09-11T00:32:29.000Z - 10 days ago

HUTCHMED (China) Ltd (HCM) Stock Down 3.2% -- Now Undervalued? GF Score: 81/100

Hutchmed upgraded to Buy from Hold at HSBC

2026-09-08T14:00:20.000Z - 13 days ago

Hutchmed upgraded to Buy from Hold at HSBC

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

Thu, 03 Sep 2026 13:03:17 -0400 - 18 days ago

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

Hutchmed upgraded to Buy from Hold at Daiwa

2026-09-03T16:05:17.000Z - 18 days ago

Hutchmed upgraded to Buy from Hold at Daiwa

Hutchmed rises 13.7%

2026-09-03T14:05:53.000Z - 18 days ago

Hutchmed rises 13.7%

HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal

2026-09-03T13:57:02.000Z - 18 days ago

HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal

GSK

HUTCHMED (China) Transcript: Status update

Sep 3, 2026, 7:30 AM EDT - 18 days ago

HUTCHMED (China) Transcript: Status update

HUTCHMED (China) Press release: Status update

Sep 3, 2026, 7:30 AM EDT - 18 days ago

HUTCHMED (China) Press release: Status update

HUTCHMED (China) Slides: Status update

Sep 3, 2026, 7:30 AM EDT - 18 days ago

HUTCHMED (China) Slides: Status update

Hutchmed, GSK enter HMPL-A830 commercialization agreement

2026-09-03T09:10:27.000Z - 18 days ago

Hutchmed, GSK enter HMPL-A830 commercialization agreement

GSK

HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

Sep 3, 2026, 1:48 AM EDT - 18 days ago

HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

GSK HCM

HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%

2026-09-03T05:32:46.000Z - 18 days ago

HUTCHMED Licenses HMPL-A830 To GSK In $1.295 Bln Deal For Cancer Therapy; Stock Up 14%

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

Sep 3, 2026, 12:00 AM EDT - 18 days ago

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

HCM

HUTCHMED Reports Positive Phase 3 SANOVO Data For ORPATHYS Plus TAGRISSO In EGFR-Mutant NSCLC

2026-08-31T05:49:51.000Z - 21 days ago

HUTCHMED Reports Positive Phase 3 SANOVO Data For ORPATHYS Plus TAGRISSO In EGFR-Mutant NSCLC

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

Aug 30, 2026, 8:00 PM EDT - 22 days ago

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

HCM

Hutchmed's ATLED Wins Conditional Approval From NMPA For Intrahepatic Cholangiocarcinoma

2026-08-28T05:03:53.000Z - 24 days ago

Hutchmed's ATLED Wins Conditional Approval From NMPA For Intrahepatic Cholangiocarcinoma

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

Aug 27, 2026, 8:00 PM EDT - 25 days ago

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

HCM

HUTCHMED's ORPATHYS-TAGRISSO Combo Shows Significant PFS, OS Benefit In Phase III Trial

2026-08-17T06:59:34.000Z - 5 weeks ago

HUTCHMED's ORPATHYS-TAGRISSO Combo Shows Significant PFS, OS Benefit In Phase III Trial

Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso

2026-08-17T00:25:05.000Z - 5 weeks ago

Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

Aug 16, 2026, 8:00 PM EDT - 5 weeks ago

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

HCM

HUTCHMED H1 Earnings Call Highlights

Thu, 30 Jul 2026 13:08:14 -0400 - 7 weeks ago

HUTCHMED H1 Earnings Call Highlights

HUTCHMED (China) Earnings Call Transcript: H1 2026

Jul 30, 2026, 8:00 AM EDT - 7 weeks ago

HUTCHMED (China) Earnings Call Transcript: H1 2026

HUTCHMED (China) Quarterly report: H1 2026

Jul 30, 2026, 8:00 AM EDT - 7 weeks ago

HUTCHMED (China) Quarterly report: H1 2026

HUTCHMED (China) Slides: H1 2026

Jul 30, 2026, 8:00 AM EDT - 7 weeks ago

HUTCHMED (China) Slides: H1 2026

Hutchmed price target lowered to $14 from $16 at Goldman Sachs

2026-07-23T10:06:10.000Z - 2 months ago

Hutchmed price target lowered to $14 from $16 at Goldman Sachs

Hutchmed price target lowered to $17 from $20 at BofA

2026-07-07T13:20:12.000Z - 2 months ago

Hutchmed price target lowered to $17 from $20 at BofA

Hutchmed announces China NMPA approval for Orpathys NDA

2026-07-02T09:05:10.000Z - 2 months ago

Hutchmed announces China NMPA approval for Orpathys NDA

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

Jul 2, 2026, 4:30 AM EDT - 2 months ago

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

HCM

HUTCHMED to Announce 2026 Half-Year Financial Results

Jun 30, 2026, 4:30 AM EDT - 2 months ago

HUTCHMED to Announce 2026 Half-Year Financial Results

HCM

Syndio Acquires Embrace.ai

Jun 23, 2026, 12:30 PM EDT - 3 months ago

Syndio Acquires Embrace.ai

HCM

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

Jun 16, 2026, 7:00 AM EDT - 3 months ago

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

EWTX HCM

isolved Honors Top-Performing Partners at Annual Connect for Partners Event

Jun 15, 2026, 8:30 PM EDT - 3 months ago

isolved Honors Top-Performing Partners at Annual Connect for Partners Event

HCM

isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees

Jun 15, 2026, 12:00 PM EDT - 3 months ago

isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees

HCM

Paychex Recognized as a Top WorkTech Company by TIME

Jun 15, 2026, 9:30 AM EDT - 3 months ago

Paychex Recognized as a Top WorkTech Company by TIME

HCM PAYX

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

Jun 11, 2026, 8:00 PM EDT - 3 months ago

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

HCM

Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley

2026-05-28T21:09:08.000Z - 3 months ago

Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

May 21, 2026, 8:00 PM EDT - 4 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

HCM

Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination

2026-05-21T10:10:55.000Z - 4 months ago

Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination

Hutchmed, Innovent Biologics announce China NMPA approval for NDA

2026-05-21T10:05:23.000Z - 4 months ago

Hutchmed, Innovent Biologics announce China NMPA approval for NDA

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

May 21, 2026, 6:00 AM EDT - 4 months ago

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HCM

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

May 21, 2026, 6:00 AM EDT - 4 months ago

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HCM

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites

May 20, 2026, 10:00 AM EDT - 4 months ago

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites

HCM

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms

May 18, 2026, 10:00 AM EDT - 4 months ago

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms

HCM

Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

May 13, 2026, 2:09 PM EDT - 4 months ago

Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations

HCM

Hutchmed says NDA for sovleplenib accepted in China

2026-04-29T10:46:12.000Z - 4 months ago

Hutchmed says NDA for sovleplenib accepted in China

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference

Apr 28, 2026, 10:00 AM EDT - 4 months ago

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference

HUTCHMED (China) Slides: Deutsche Bank ADR Virtual Investor Conference

Apr 28, 2026, 10:00 AM EDT - 4 months ago

HUTCHMED (China) Slides: Deutsche Bank ADR Virtual Investor Conference

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

Apr 8, 2026, 8:00 PM EDT - 5 months ago

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

HCM

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

Mar 22, 2026, 8:00 PM EDT - 6 months ago

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HCM

Hutchmed price target lowered to $20 from $21 at BofA

2026-03-10T11:30:35.000Z - 6 months ago

Hutchmed price target lowered to $20 from $21 at BofA

Hutchmed discontinues all active tazemetostat clinical trials

2026-03-09T09:40:32.000Z - 6 months ago

Hutchmed discontinues all active tazemetostat clinical trials

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

Mon, 09 Mar 2026 05:30:00 -0400 - 6 months ago

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

Hutchmed price target lowered to $21 from $22 at BofA

2026-03-06T13:16:28.000Z - 6 months ago

Hutchmed price target lowered to $21 from $22 at BofA

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

Fri, 06 Mar 2026 03:30:00 -0500 - 6 months ago

Intended Retirement of Independent Non-executive Director and changes of composition of board committees

HUTCHMED (China) Earnings Call Transcript: H2 2025

Mar 5, 2026, 7:30 PM EST - 6 months ago

HUTCHMED (China) Earnings Call Transcript: H2 2025

HUTCHMED (China) Annual report: H2 2025

Mar 5, 2026, 7:30 PM EST - 6 months ago

HUTCHMED (China) Annual report: H2 2025

HUTCHMED (China) Annual report: H2 2025

Mar 5, 2026, 7:30 PM EST - 6 months ago

HUTCHMED (China) Annual report: H2 2025

HUTCHMED (China) Slides: H2 2025

Mar 5, 2026, 7:30 PM EST - 6 months ago

HUTCHMED (China) Slides: H2 2025

HUTCHMED (China) Annual report: H2 2025

Mar 5, 2026, 7:30 PM EST - 6 months ago

HUTCHMED (China) Annual report: H2 2025

HUTCHMED to Announce 2025 Final Results

Fri, 06 Feb 2026 03:30:00 -0500 - 7 months ago

HUTCHMED to Announce 2025 Final Results

Hutchmed reports publication of SACHI results in The Lancet

2026-01-14T10:35:22.000Z - 8 months ago

Hutchmed reports publication of SACHI results in The Lancet

AZN

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

Tue, 13 Jan 2026 23:00:00 -0500 - 8 months ago

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

Hutchmed says Phase III of ESLIM-02 trial met primary endpoint

2026-01-07T00:05:12.000Z - 8 months ago

Hutchmed says Phase III of ESLIM-02 trial met primary endpoint

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Jan 6, 2026, 7:00 PM EST - 8 months ago

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

Jan 4, 2026, 7:00 PM EST - 8 months ago

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

Dec 30, 2025, 5:00 AM EST - 8 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

Dec 29, 2025, 3:35 AM EST - 8 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

Dec 16, 2025, 7:00 PM EST - 9 months ago

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

Nov 26, 2025, 7:00 PM EST - 9 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

HUTCHMED (China) Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 10:30 AM EST - 10 months ago

HUTCHMED (China) Transcript: Jefferies London Healthcare Conference 2025

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference 2025

HUTCHMED (China) Slides: FY 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

HUTCHMED (China) Slides: FY 2025

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

Nov 2, 2025, 7:00 PM EST - 10 months ago

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

HUTCHMED (China) Transcript: Status Update

Oct 31, 2025, 8:00 AM EDT - 10 months ago

HUTCHMED (China) Transcript: Status Update

HUTCHMED (China) Slides: Status Update

Oct 31, 2025, 8:00 AM EDT - 10 months ago

HUTCHMED (China) Slides: Status Update

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Oct 14, 2025, 4:30 AM EDT - 11 months ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

Oct 13, 2025, 12:00 AM EDT - 11 months ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

Oct 1, 2025, 8:00 PM EDT - 11 months ago

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

Sep 11, 2025, 8:00 PM EDT - 1 year ago

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

Sep 4, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HUTCHMED Announces Appointment of Acting Chief Executive Officer

Aug 24, 2025, 8:20 PM EDT - 1 year ago

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

Aug 19, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED (China) Earnings Call Transcript: H1 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Earnings Call Transcript: H1 2025

HUTCHMED (China) Quarterly report: H1 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Quarterly report: H1 2025

HUTCHMED (China) Slides: H1 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

HUTCHMED (China) Slides: H1 2025

HUTCHMED to Announce 2025 Half-Year Financial Results

Jul 3, 2025, 4:30 AM EDT - 1 year ago

HUTCHMED to Announce 2025 Half-Year Financial Results

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Jun 30, 2025, 4:30 AM EDT - 1 year ago

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED (China) Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 2:40 PM EDT - 1 year ago

HUTCHMED (China) Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

HUTCHMED (China) Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

HUTCHMED (China) Transcript: Jefferies Global Healthcare Conference 2025

HUTCHMED (China) Slides: Corporate Presentation

Jun 5, 2025, 2:00 AM EDT - 1 year ago

HUTCHMED (China) Slides: Corporate Presentation

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

Jun 4, 2025, 7:45 PM EDT - 1 year ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED (China) Transcript: Investor Update

Jun 2, 2025, 8:30 PM EDT - 1 year ago

HUTCHMED (China) Transcript: Investor Update

HUTCHMED (China) Press release: Investor Update

Jun 2, 2025, 8:30 PM EDT - 1 year ago

HUTCHMED (China) Press release: Investor Update

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

Jun 1, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

May 22, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference

May 15, 2025, 10:30 AM EDT - 1 year ago

HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference

HUTCHMED (China) Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 2:20 PM EDT - 1 year ago

HUTCHMED (China) Transcript: Bank of America 2025 Healthcare Conference

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Apr 23, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

Apr 21, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Mar 21, 2025, 6:00 AM EDT - 1 year ago

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

Mar 20, 2025, 5:30 AM EDT - 1 year ago

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

US pharma restrictions won't affect Hutchmed operations, says CEO

Mar 20, 2025, 12:46 AM EDT - 1 year ago

US pharma restrictions won't affect Hutchmed operations, says CEO

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Mar 19, 2025, 8:00 PM EDT - 1 year ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Avocado_smash
Avocado_smash Sep. 21 at 9:41 PM
$HCM
0 · Reply
OnlyFibs
OnlyFibs Sep. 9 at 12:23 AM
RECAP 9/8 +Pos Comments: $HCM + HSBC $BCRX + TD Cowen $VIK + UBS RECAP 9/8 -Neg Comments: $CRM - Accountability Research
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 8 at 8:00 PM
RECAP 9/8 +Pos Comments: $HCM + HSBC $BCRX + TD Cowen $VIK + UBS RECAP 9/8 -Neg Comments: $CRM - Accountability Research Live Breaking trading news www.openoutcrier.com
0 · Reply
DekmarTrades
DekmarTrades Sep. 3 at 1:29 PM
ENTIRE LIST OF CREDIBLE TOP GAINERS WITH NEWS: $MIMI $HCM $DLTH $GCO $SPWR
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 3 at 12:51 PM
$HCM (+12.5% pre) HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy https://ooc.bz/l/113161
0 · Reply
npcpaperboy
npcpaperboy Sep. 3 at 11:16 AM
$HCM news no vol
0 · Reply
STACKD0E
STACKD0E Sep. 3 at 10:18 AM
$HCM $FFAI 👁
0 · Reply
Polip
Polip Sep. 3 at 10:11 AM
$HCM Again this is very mispriced. should be trading at 40 $XBI
0 · Reply
notreload_ai
notreload_ai Sep. 3 at 9:51 AM
$HCM licenses HMPL-A830, a KRAS-EGFR ATTC, to $GSK for $110M upfront. Trials start H2 2026 in colorectal, pancreatic and lung cancers. https://notreload.xyz/xy/hutchmed-licenses-kras-egfr-cancer-drug-to-gsk/
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 31 at 12:18 PM
$HCM (+3.0% pre) HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China https://ooc.bz/l/112764
0 · Reply
flychicken1991
flychicken1991 Aug. 17 at 2:50 PM
$HCM Positive (88%): shares face upward price pressure because successful late-stage trial results increase the perceived probability that savolitinib can progress toward broader regulatory and commercial use. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/908f4ef0a39835b6?utm_source=stocktwits&utm_medium=story_url
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 17 at 12:19 PM
$HCM (+6.6% pre) HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO® https://ooc.bz/l/111337
0 · Reply
Polip
Polip Aug. 17 at 9:34 AM
$HCM severely mispriced $AZN $XBI
0 · Reply
anvesti
anvesti Aug. 12 at 7:42 PM
Anvesti opened a long position $HCM · Entry $12.27 Model: ml_model_v3 · Score: 75.5
0 · Reply
interestingtimes
interestingtimes Jul. 31 at 11:45 PM
$HCM https://www.investing.com/news/transcripts/earnings-call-transcript-hutchmed-posts-solid-h1-2026-growth-stock-edges-up-93CH-4824518
0 · Reply
EarningsInsider
EarningsInsider Jul. 30 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-30-hutchison-china-meditech-limited-stock/ $HCM HUTCHMED Earnings Transcript
0 · Reply
anvesti
anvesti Jul. 29 at 7:56 PM
Anvesti closed a long position $HCM 🟢 +5.03% $10.84 → $11.38 Model: ml_model_v3 · Score: 75.5 Reason: Earnings Protection · 19 days
0 · Reply
LewisDaKat
LewisDaKat Jul. 2 at 8:30 PM
$HCM HUTCHMED Announces NMPA Approval for ORPATHYS for the treatment of Gastric Cancer Patients with MET Amplification https://marketwirenews.com/stock/hcm/news/hutchmed-announces-nmpa-approval-for-orpathys-xae-fo-7272928322823748.html?utm_source=stocktwits
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 2 at 12:50 PM
$HCM (+7.1% pre) HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification https://ooc.bz/l/106753
0 · Reply
anvesti
anvesti Jul. 1 at 7:53 PM
Anvesti opened a long position $HCM · Entry $10.84 Model: ml_model_v3 · Score: 75.5
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 12 at 12:20 PM
$HCM (+4.9% pre) HUTCHMED reports positive phase III data for sovleplenib in wAIHA https://ooc.bz/l/104982
0 · Reply